Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Replimune Group, Inc. - Common Stock (NQ:REPL)

8.630 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Replimune Group, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Dow Falls 100 Points; ISM Services PMI Increases In November ↗
U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded down 0.28% to 36,103.52 while the NASDAQ rose 0.32% to 14,230.64. The S&P... 
Via Benzinga
Topics Stocks
News headline image
The Latest Analyst Ratings for Replimune Group ↗
 
Via Benzinga
News headline image
Analyst Ratings for Replimune Group ↗
 
Via Benzinga
Replimune Group Inc. (NASDAQ: REPL) Making Surprising Moves in Monday Session
Via Investor Brand Network
News headline image
Why Is Replimune (REPL) Stock Down 48% Today? ↗
Replimune stock is dropping on Tuesday as investors in REPL shares react to a clinical trial missing both of its primary endpoints. 
Via InvestorPlace
News headline image
US Stocks Down; JM Smucker Posts Upbeat Earnings ↗
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Tuesday. Following the market opening Tuesday, the Dow traded down 0.23% to 36,120.88 while the NASDAQ fell... 
Via Benzinga
Topics Stocks
News headline image
What's Going On With Cancer-Focused Replimune Stock Today? ↗
Replimune Group Inc (NASDAQ: REPL) announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemiplimab for locally advanced or metastatic cutaneous  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Recap: Replimune Group Q4 Earnings ↗
 
Via Benzinga
Analyst Ratings for Replimune Group ↗
 
Via Benzinga
News headline image
Replimune Group: Q2 Earnings Insights ↗
Replimune Group (NASDAQ:REPL) reported its Q2 earnings results on Thursday, November 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Replimune and Incyte Enter into Clinical Trial Collaboration and Supply Agreement to Evaluate RP1 and INCB99280 in Patients with Cutaneous Squamous Cell Carcinoma
From Incyte
Via Business Wire
News headline image
Stock Market Rally Broadens Out; Apple Unveils Vision Pro, SEC Sues Binance, Coinbase: Weekly Review ↗
The Nasdaq held near 52-week highs while small caps ramped up. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes ↗
ImmunoGen and Day One gained Monday on their updates at a cancer treatment conference. 
Via Investor's Business Daily
News headline image
Why Amedisys Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers Sono Group N.V. (NYSE: SEV) shares surged 152.7% to $0.4367. Sono Group applied to Insolvency Court of Munich, Germany, to permit opening of self-administration proceeding. 
Via Benzinga
News headline image
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month ↗
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
News headline image
Analyst Beefs Up Replimune Price Target As Recent Data Validates Treatment Platform ↗
Last Thursday, Replimune Group Inc (NASDAQ: REPL) announced an initial data snapshot from the first 75 patients from the anti-PD1 failed cutaneous melanoma cohort of the IGNYTE clinical. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗
 
Via Benzinga
News headline image
PayPal To Rally Around 47%? Here Are 10 Other Price Target Changes For Monday ↗
 
Via Benzinga
News headline image
Why Prometheus Biosciences Shares Are Trading Higher By Over 184%? Here Are 55 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 184.2% to $102.49 after the company announced results for PRA023 in both ARTEMIS-UC Phase 2 and APOLLO-CD Phase 2a studies. ARTEMIS-UC... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Replimune Shares Surge After Early Data From Pretreated Melanoma Patients ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Replimune Gets 33% Price Target Bump Ahead Of Upcoming Readouts. Analyst Lists The Catalysts ↗
 
Via Benzinga
News headline image
Wells Fargo To Surge Around 20%? Here Are 5 Other Price Target Changes For Monday ↗
Goldman Sachs raised Wells Fargo & Company (NYSE: WFC) price target from $46 to $48. Goldman Sachs analyst Richard Ramsden upgraded the stock from Neutral to Buy. Wells Fargo shares rose 1.1% to $40.68... 
Via Benzinga
News headline image
PreMarket Prep: Looking For Biotech Bargains With This Wedbush Analyst ↗
Biotechnology is one sector that peaked ahead of the S&P 500 index. While the S&P 500 index did not peak until January, the SPDR Biotech (NYSE: XBI) peaked in February 2021 and is now 60% lower than... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.